Table 5.
Patient characteristics and treatment outcomes.
| RT-group | CCRT-group | P-value | |||
|---|---|---|---|---|---|
| Patient characteristics | Number of patients | 21 | 20 | ||
| Median age | 67 | 59 | |||
| Histology | SCC | 21 | 20 | ||
| Others | 0 | 0 | |||
| Dose of nedaplatin administered, mg/m2 | Median (range) | — | 35 (10–45) | ||
| Courses of nedaplatin administered | Median (range) | — | 5 (2–5) | ||
|
| |||||
| Treatment outcome | PFS, months | Median (range) | 7 (0–60) | 60 (0–60) | .0015 |
| Mean | 21.4 | 43.3 | |||
| OS, months | Median | 29 (1–60) | 60 (5–60) | .0364 | |
| Mean | 32.3 | 47 | |||
| Duration of radiotherapy | Median (range) | 47 (41-61) | 45 (40–57) | NS | |
| Patients with recurrence (%) | 14 (66.7%) | 7 (35%) | NS | ||
| Patients with grade 3-4 acute toxicity (%) | 1 (4.8%) | 10 (50%) | .0014 | ||
| Patients with grade 3-4 late toxicity (%) | 0 (0%) | 2 (10%) | NS | ||
PFS: progression-free survival, OS: overall survival, SCC: squamous cell carcinoma, CCR: concurrent chemoradiotherapy, RT: radiotherapy.